Abstracts Archive - Page 1052 of 2607 - ACR Meeting Abstracts

Abstract Number: 1678 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis
Haidy Adel Youssef¹ and Mehrnaz Hojjati ², ¹Riverside Community Hospital/ UCR School of Medicine Internal Medicine Residency Program, Corona, CA, ²Department of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: ANCA associated vasculitis patients have a wide spectrum of pulmonary involvement in the form nodular disease (especially peri-bronchial nodules), cavitating lesions, diffuse alveolar hemorrhage and less…
Abstract Number: 1679 • 2019 ACR/ARP Annual Meeting
Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases are both forms of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Standard of…
Abstract Number: 1680 • 2019 ACR/ARP Annual Meeting
Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases to anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Standard of care (SOC)…
Abstract Number: 1681 • 2019 ACR/ARP Annual Meeting
The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)
Zachary Wallace¹, Xiaoqing Fu ¹, Yuqing Zhang ², John Stone ³ and Hyon K. Choi ², ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a small vessel vasculitis associated with an intense inflammatory state. AAV patients are at a 2-fold higher risk of cardiovascular…
Abstract Number: 1682 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Granulomatosis with polyangiitis (GPA, formerly known and Wegener’s granulomatosis) is a major subtype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by granulomatous inflammation of…
Abstract Number: 1683 • 2019 ACR/ARP Annual Meeting
Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort
Silvia Sartorelli ¹, Pascal Cohen ², Bertrand Dunogue ², Alexis Régent ², Xavier Puéchal for the French Vasculitis Study Group ², Luc Mouthon ², Loic Guillevin ² and Benjamin Terrier², ¹Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ²National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis characterized by blood and tissue eosinophilia, and asthma. Its cardiac involvement is a major…
Abstract Number: 1684 • 2019 ACR/ARP Annual Meeting
Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual
Paolo Delvino ¹, Federica Sardanelli ², Pascal Cohen ³, Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³, Loic Guillevin ³ and Benjamin Terrier³, ¹Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Vercelli, Italy, ²Department of Internal Medicine , Clinical Immunology Unit of Genoa and Policlinico San Martino, Genova, Italy, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) require glucocorticoids (GCs) and immunosuppressants (IS) to induce and maintain remission. At the era of highly…
Abstract Number: 1685 • 2019 ACR/ARP Annual Meeting
Inpatient Burden, Expenditures and Comorbidities of Polyarteritis Nodosa: National Inpatient Sample 2014
Patompong Ungprasert¹, Matthew Koster ², Wisit Cheungpasitporn ³, Karn Wijarnpreecha ⁴, Charat Thongprayoon ² and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mayo Clinic Rochester, Rochester, MN, ³University of Mississippi Medical Center, Jackson, MS, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Due to the rarity of polyarteritis nodosa (PAN), no study has ever investigated inpatient characteristics, healthcare utilization and frequency of comorbidities of patients with…
Abstract Number: 1686 • 2019 ACR/ARP Annual Meeting
Risk of Vasculitis Associated with Inflammatory Bowel Diseases: Evidence for a Role of TNF-α Blockers
Benjamin Terrier¹, Laurent Beaugerie ², Philippe Seksik ², Harry Sokol ² and Julien Kirchgesner ², ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²Saint-Antoine Hospital, Paris, France
Background/Purpose: An increased risk of side effects, especially infections, has been reported among patients receiving tumor necrosis factor (TNF)-α blockers. Some leukocytoclastic cutaneous vasculitides reportedly occurred…
Abstract Number: 1687 • 2019 ACR/ARP Annual Meeting
Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis
Thomas Bettuzzi ¹, Alban Deroux ², Marie Jachiet ³, Meryem-Maud Farhat ⁴, Julien Wipff ¹, Marc Fabre ⁵, Laurence Bouillet ², Nora Kramkimel ¹, Selim Aractingi ¹, Nicolas Dupin ¹ and Benjamin Terrier⁶, ¹Cochin Hospital, Paris, France, ²CHU, Grenoble, France, ³Saint Louis Hospital, Paris, France, ⁴CHRU, Lille, France, ⁵CH, Bourgoin-Jailleu, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Urticarial vasculitis (UV) is a rare disease characterized by dermal capillary inflammation responsible for long-lasting urticarial lesions. UV can be separated into 2 different…
Abstract Number: 1688 • 2019 ACR/ARP Annual Meeting
Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
Benjamin Terrier¹, Jonathan London ², Fabrice Bonnet ³, Diane Cerutti ⁴, Nathalie Costedoat-Chalumeau ⁵, Elisabeth Diot ⁶, Yasmina Ferfar ⁷, Aurélie Hummel ⁸, Gilles Kaplanski ⁹, Isabelle Marie ¹⁰, Thomas Quémeneur ¹¹, Patricia Rullier ¹², Patricia Senet ¹³, Noémie Le Gouellec ¹⁴, Julie Lejeune ⁷, David Saadoun ¹⁵ and Patrice Cacoub ¹⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²Croix Saint-Simon Hospital, Paris, France, ³CHU, Bordeaux, France, ⁴CH, Toulon, France, ⁵Cochin University Hospital, Paris, France, ⁶APHP, Tours, France, ⁷Pitié-Salpétrière Hospital, Paris, France, ⁸APHP, Paris, France, ⁹CHU, Marseille, France, ¹⁰CHU, Rouen, France, ¹¹CH Valenciennes, Valenciennes, France, ¹²CHU, Montpellier, France, ¹³Tenon Hospital, Paris, France, ¹⁴CH, Valenciennes, France, ¹⁵AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France
Background/Purpose: A previous retrospective study suggested superiority of glucocorticoids (GCs) plus rituximab (RTX) compared to GCs alone to induce complete clinical response in non-infectious cryoglobulinemia…
Abstract Number: 1689 • 2019 ACR/ARP Annual Meeting
Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa
Alice Canzian ¹, Omer Karadag ², Anne Contis ³, François Maurier ⁴, Silvia Sartorelli ⁵, Laure Denis ⁶, Sébastien Sanges ⁷, Claire de Moreuil ⁸, Cécile-Audrey Durel ⁹, Stéphane Durupt ¹⁰, Marie Jachiet ¹¹, Diane Rouzaud ¹², Carlo Salvarani ¹³, Franco Schiavon ¹⁴, Lorenzo Dagna ¹⁵, Fabrice Bonnet ¹⁶, David Jayne ¹⁷, Loic Guillevin ¹⁸ and Benjamin Terrier¹, ¹Cochin Hospital, Paris, France, ²Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ³Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France, Bordeaux, France, ⁴Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ⁵Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, ⁶Clermont-Ferrand Hospital, Clermont-Ferrand, France, ⁷CHRU Lille, Lille, France, ⁸CHU Brest, Brest, France, ⁹Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁰Lyon Hospital, Lyon, France, ¹¹Saint Louis Hospital, Paris, France, ¹²Bichat Hospital, Paris, France, ¹³Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁴Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ¹⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, ¹⁶CHU Bordeaux, Bordeaux, France, ¹⁷Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁸National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis of medium- and small-sized arteries, not associated with antineutrophil cytoplasmic antibodies (ANCA). Conventional treatments include…
Abstract Number: 1690 • 2019 ACR/ARP Annual Meeting
The Long-term Outcome of Patients with Arthritis of Behçet’s Disease
Hirotoshi Kikuchi¹, Takafumi Tomizuka ¹, Kurumi Asako ¹, Hajime Kono ¹ and Shunsei Hirohata ², ¹Teikyo University School of Medicine, Tokyo, Japan, ²Nobuharra Hospital & Institute of Biomechanics, Tokyo, Japan
Background/Purpose: Behçet’s disease (BD) is characterized by recurrent aphthous stomatitis, eye lesions, skin lesions, and genital ulcer. In addition to these symptoms, Behçet’s disease is…
Abstract Number: 1691 • 2019 ACR/ARP Annual Meeting
Efficacy of TNF α Inhibitors for Refractory Vascular Behcet’s Disease: A Multicenter Observational Study of 27 Patients
Aysun Aksoy ¹, Ayten Yazici ², Ahmet Omma ³, Ayşe Cefle ⁴, Fatos Onen ⁵, Unal Tasdemir ⁶, Tulin Ergun ⁷, Haner Direskeneli ⁸ and Fatma Alibaz-Oner⁹, ¹Marmara University Faculty of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom, Istanbul, Istanbul, Turkey, ²Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ³Health Sciences University, Ankara Numune Training and Research Hospital, Department of Rheumatology, Ankara, Turkey, ⁴Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ⁵Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ⁶Dokuz Eylul University, School of Medicine Division of Internal Medicine Rheumatology Department, izmir, Turkey, ⁷Marmara University School of Medicine Dermatology Department, istanbul, Turkey, ⁸Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ⁹Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey
Background/Purpose: Vascular involvement is one of the major causes of morbidity and mortality in Behcet’s Disease (BD) patients. Immunosuppressive (IS) agents are the mainstay of…
Abstract Number: 1692 • 2019 ACR/ARP Annual Meeting
Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice
Iñigo Gonzalez-Mazon¹, Lara Sanchez-Bilbao ², Belén Atienza-Mateo ², Jose Luis Martín-Varillas ², DIANA PRIETO- PENA ¹, Vanesa Calvo-Río ³, Rosalia Demetrio ⁴, Natalia Palmou-Fontana ¹, Javier Loricera ⁵, Emma Beltrán Catalán ⁶, Marisa Hernández Garfella ⁷, Elia Valls-Pascual ⁸, Antonio Atanés ⁹, Miguel Cordero Coma ⁹, Joan M Nolla ¹⁰, Carmen carrasco-Cubero ¹¹, Julio Sánchez ¹², Miguel A Gonzalez-Gay ² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵H.U. Marques de Valdecilla, Santander, Spain, ⁶Hospital del Mar, Barcelona, Spain, ⁷H.G.U. Valencia, Valencia, ⁸Dr Peset University Hospital, Valencia, Spain, ⁹HUAC La Coruña, Coruña, Spain, ¹⁰Hospital Universitari de Bellvitge, Hospitalet, Spain, ¹¹CHU de Badajoz, Badajoz, Spain, ¹²Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Ocular involvement in Behçet’s disease (BD) is a potential severe and disabling complication. Anti-TNF-α agents have shown an improvement of visual outcome in BD-related…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].